GZ402668

DRUG2 trials

Sponsors

Genzyme, a Sanofi Company, Sanofi

Conditions

Progressive Multiple Sclerosis

Phase 1

A First-in-human, Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis

CompletedNCT02282826

Genzyme, a Sanofi CompanyProgressive Multiple Sclerosis

Start: 2014-10-31End: 2016-03-31Updated: 2016-04-13

A Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis

CompletedNCT02977533

SanofiProgressive Multiple Sclerosis

Start: 2016-12-01End: 2018-05-16Updated: 2022-04-25

Related Papers

Phase 1 Trials of Gatralimab, a Next-Generation Humanized Anti-CD52 Monoclonal Antibody, in Participants with Progressive Multiple Sclerosis.

2024-09-09